Ireland
--:--IST
Starting soon Not applicable

Comparison of Serratus Posterior Superior Intercostal Plane Block and Deep Serratus Anterior Plane Block After Video-Assisted Thoracoscopic Surgery

NCT07553195 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-11-30
Last updated
2026-05-11

Condition(s) studied

Postoperative PainVideo Assisted Thoracic Surgery (VATS)Serratus Posterior Superior Intercostal Plane BlockDeep Serratus Anterior Plane Block

Investigational drug(s) / intervention(s)

Serratus Posterior Superior Intercostal Plane (SPSIP) blockDeep Serratus Anterior Plane Block (Deep SAP)

Serratus Posterior Superior Intercostal Plane (SPSIP) block: Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.

Deep Serratus Anterior Plane Block (Deep SAP): Patients in this group will receive an ultrasound-guided Deep Serratus Anterior Plane Block (Deep SAP) with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus anterior muscle and the external intercostal muscles at the level of the 5th rib in the mid-axillary line.

Study summary

This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Deep Serratus Anterior Plane Block in patients undergoing Video-Assisted Thoracoscopic Surgery. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, Quality of recovery assessed using the QoR-15 questionnaire.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18-65 years * ASA physical status I-III * Scheduled for elective video-assisted thoracoscopic surgery * Body mass index (BMI) between 18 and 35 kg/m² * Ability to understand and use the patient-controlled analgesia (PCA) device * Ability to provide written informed consent Exclusion Criteria: * Refusal to participate * Allergy to local anesthetics * Infection at the injection site * Coagulopathy or ongoing anticoagulant therapy * Chronic opioid use or opioid dependence * Severe hepatic or renal insufficiency * Pregnancy or breastfeeding * Cognitive impairment or inability to communicate pain scores * Body mass index (BMI) \<18 or \>35 kg/m²

Primary outcome measure(s)

  • Postoperative pain intensity assessed using the Visual Analog Scale (VAS) — 0, 1, 4, 8, 12, and 24 hours after surgery
    Postoperative pain intensity (VAS score) Postoperative pain will be assessed using the visual analog scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent greater pain intensity. Measurements will be recorded at predefined time points within the first 24 hours after surgery.

Trial sites (1)

FacilityCityRegionStatus
Antalya City Hospital Antalya Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07553195 on ClinicalTrials.gov ↗ ← All trials in Turkey